Clinical Decision Support and the WISeR Vendor Ecosystem

Prior authorization has existed in Medicare Advantage since the beginning of the program. It has never existed in Original Medicare fee-for-service, where the historical design principle was that CMS would pay claims after the fact and use retrospective review, audits, and fraud enforcement to address inappropriate utilization. WISeR breaks that principle. Launched January 1, 2026, the model introduces pre-service authorization requirements into FFS Medicare for the first time at meaningful scale, covering 14 service categories across six states and doing so through AI-powered clinical decision support vendors rather than through the Medicare Administrative Contractors that have always been the operational infrastructure of FFS administration.

The consequence is a contract market that did not previously exist. CMS has selected six technology companies to operate as WISeR model participants. Those companies — not the MACs, not CMS directly — are the entities reviewing clinical documentation, issuing authorization determinations within 72 hours, managing appeals workflows, and eventually qualifying providers for gold-card exemptions. What gets built to operate in this market, and what it takes to compete for it, defines the vendor landscape this article maps.

The WISeR Contract Structure

#

The model runs from January 1, 2026 through December 31, 2031. It operates in New Jersey, Ohio, Oklahoma, Texas, Arizona, and Washington — each state assigned to a specific model participant. Providers and suppliers delivering any of the 14 covered service categories to FFS Medicare beneficiaries in those states face a functionally mandatory PA requirement: they can submit a prior authorization request through the model participant’s electronic portal, submit through their MAC (Noridian, Novitas, or CGS, depending on jurisdiction) and have it routed to the participant, or skip the request and face automatic prepayment medical review. In practice, the third path is an administrative exposure most providers will avoid, making WISeR’s voluntary designation largely nominal.

The 14 covered service categories were chosen for their documented vulnerability to fraud, waste, and abuse in FFS Medicare. Skin substitutes are the most prominent — CMS separately reduced Part B payment for most skin substitute products in 2026 from biologic-based pricing to a flat rate of $127.28 per square centimeter, classifying them as incident-to supplies, reflecting how aggressively the administration views this category. Electrical nerve stimulators, spinal procedures, and knee arthroscopy for osteoarthritis round out the major service categories. These are elective, non-emergent procedures with documented patterns of overutilization — the clinical profile that makes them defensible PA targets and that requires condition-specific clinical logic, not generic AI, to review appropriately.

The 72-hour turnaround requirement applies from the moment a provider submits to a participant portal. CMS has stated it will take corrective action against participants that cannot meet turnaround time, including payment penalties. The gold-card mechanism — which would exempt providers with consistent approval histories from the PA requirement — is in development with further details expected by mid-2026. FedRAMP certification is required for all participant systems, as is compliance with FISMA regulations, CMS Information Systems Security and Privacy Policy, and HIPAA business associate agreements covering FFS Original Medicare data. The data security bar for operating in this market is therefore federal government infrastructure-grade, not commercial healthcare standards.

The Six Participants and Their Positioning

#

Cohere Health is operating WISeR in Texas and is the participant with the most directly relevant prior authorization AI infrastructure. Cohere’s Unify platform processes over 12 million prior authorization requests annually across more than 660,000 providers. Its installed base is primarily MA plans — Humana, Geisinger, Medical Mutual — which makes WISeR an expansion of an existing operational capability into FFS rather than a new market entry. In May 2025, Cohere closed a $90 million Series C led by Temasek, bringing total funding to approximately $200 million. Cohere’s September 2025 acquisition of ZignaAI extended the platform into payment integrity, and the company launched Cohere Review Assist for acute inpatient authorization in 2025, demonstrating an intentional expansion beyond outpatient PA. The Cohere Align product, launched 2025, personalizes the PA process by analyzing providers’ historical approval patterns and dynamically adjusting submission requirements — the commercial precursor to the WISeR gold-card mechanism. Cohere reports that approximately 80 percent of PA submissions through Align are streamlined for pre-approved providers, with 55 percent reduction in provider submission time.

Genzeon Corporation is operating in New Jersey. The company’s HIP One platform takes an explicitly layered approach: robotic process automation handles deterministic intake tasks, agentic AI handles clinical documentation summarization and guideline comparison, and human clinicians review complex or borderline cases. Genzeon’s positioning is the automation-plus-human-judgment hybrid, which reflects both the actual clinical complexity of the covered service categories and the CMS requirement that automated determinations be explainable and auditable. Black-box models do not qualify under WISeR’s transparency standards.

Innovaccer is operating in Ohio. Its WISeR deployment is a natural extension of the population health analytics and care management infrastructure described in MCR-06.09. Innovaccer’s federal contract data access relationships, including its existing CMS partnerships, create structural advantages in the data pipeline that WISeR requires — claims history analysis, EHR data integration, and real-time eligibility verification across a large attributed population.

Humata Health is operating in Oklahoma. Virtix Health is operating in Washington. Zyter is operating in Arizona. Each brings a different technical architecture to the same operational problem: applying condition-specific clinical logic to PA requests within a 72-hour window, integrating with provider EHR systems to receive clinical documentation, and generating determinations that are defensible under CMS audit.

The competitive dynamic among these six participants is not primarily a head-to-head market. Each has a defined geographic assignment. The competition is for what comes after: WISeR’s national expansion, if the six-state pilot demonstrates adequate performance and CMS has signaled that it envisions expansion without waiting the full six-year model horizon. Healthcare attorneys and industry analysts have noted that the administration’s posture toward FFS utilization management makes WISeR’s scope extension likely — the question is timeline and service category expansion, not whether the model survives.

What a New Entrant Would Need

#

The technical requirements for WISeR participation are steep enough to have produced only six qualified entrants in the initial selection. A company seeking to participate in future WISeR expansion or analogous models would need:

Condition-specific clinical logic for each covered service category. A WISeR-grade skin substitute authorization tool requires trained models built on clinical guidelines for wound care appropriateness criteria, documented clinical indications, and the specific Medicare coverage policies governing each product category. The clinical depth required is not achievable with a general-purpose LLM prompted to review medical records. It requires models built on annotated clinical data from each service domain.

CMS-grade data infrastructure. FedRAMP certification, FISMA compliance, and CMS Authority to Operate approval are prerequisites, not competitive advantages. The pipeline connecting provider EHR data to the participant’s decision support engine requires FHIR-compliant data exchange and integration with the major EHR platforms — principally Epic and Oracle Health — that represent the majority of provider clinical workflow. A participant that requires providers to manually upload documentation will not meet the 72-hour turnaround requirement at scale.

Explainable AI architecture. CMS’s requirement that automated determinations be auditable and explainable excludes the black-box model approaches that optimize for prediction accuracy at the cost of interpretability. Each determination needs a documented rationale — specific clinical criteria met or not met, specific documentation reviewed — that survives an appeals process conducted by a clinician with relevant expertise. The compliance infrastructure for that auditability layer is as demanding as the AI model itself.

Clinical review staff. Automated AI handles the straightforward cases. Cases that the AI cannot resolve — edge cases, complex comorbidity presentations, documentation gaps — require human clinicians with the specific specialty expertise relevant to each covered service. A participant without sufficient clinical staff to handle the volume of manual review cases that automation escalates will face determination backlogs that violate the 72-hour requirement.

The API Infrastructure and Interoperability Requirements

#

CMS’s interoperability rulemaking has been building the data infrastructure that WISeR requires for several years. The Prior Authorization API requirement under the CMS Interoperability and Prior Authorization Final Rule mandates that MA plans, Medicaid managed care organizations, and CHIP programs expose PA status information through FHIR APIs to providers and, eventually, patients. WISeR participants are required to implement FHIR-compliant provider-facing portals for PA submission and status tracking.

The Improving Seniors’ Timely Access to Care Act, which passed the House in 2022 and remains pending in the Senate, would codify real-time PA status API requirements into statute for MA plans and create the machine-readable PA infrastructure that would reduce the information asymmetry between providers and authorization entities. If enacted, it would accelerate the interoperability environment within which WISeR operates. In the meantime, the CMS rulemaking framework is building toward it.

ONC certification requirements apply when a clinical decision support tool meets the statutory definition of a decision support intervention under the 21st Century Cures Act — when it analyzes patient-specific data to generate a recommendation or alert that a clinician would reasonably rely on for clinical decision-making. WISeR participants operating AI tools that generate authorization determinations are in a position that requires careful legal analysis of whether ONC certification is triggered. CMS has designed WISeR to route complex cases to human clinical review precisely to preserve the human-in-the-loop requirement that keeps the automated component outside the highest-risk regulatory category.

The Beneficiary Dimension

#

WISeR introduces a kind of administrative friction that Medicare FFS beneficiaries have never experienced. A beneficiary in Texas who needs a wound care procedure with a skin substitute has, for the first time, a care pathway that includes prior authorization — a step they may not understand is happening, and whose denial they may not know how to appeal.

The provider faces the administrative burden of the PA submission. The beneficiary faces the consequence of a denial. The appeals infrastructure for WISeR determinations follows the existing Medicare appeals pathway — a five-level process designed for institutional administrative capacity, not for individual beneficiaries without legal or benefits counseling. SHIP counselors and ADRC staff in the six WISeR states are already fielding questions about denial appeals that they have not previously needed to answer for FFS patients.

The FHIR API infrastructure that CMS is building for provider-facing PA transparency creates, as a byproduct, the data availability that would allow beneficiary-facing tools to track PA status, explain denial rationale, and identify appeal options. The tools that operate in that beneficiary-facing space are distinct from the clinical decision support vendors operating on the provider side. They are building in the gap that WISeR creates on the patient side — a need that, as of early 2026, is not yet served by any product with meaningful scale.

Related Reading

#

MCR-01_03 WISeR: Prior Authorization Comes to Traditional Medicare MCR-12_04 The HealthTech Company Ecosystem: What Medicare Policy Actually Allows vs. What Companies Claim